Point-Of-Sale Rebates May Be Added To US Senate Finance Drug Pricing Bill

Legislation clears committee with no major changes. However, the number of Republicans opposing the bill due to concerns over price inflation rebates portend difficulties ahead for a floor vote.

Dollars & Pills

US Senate Finance Committee legislation to lower drug costs in Medicare and Medicaid could be amended before it reaches the Senate floor to include provisions requiring that Medicare D plans pass through rebates to offset beneficiary cost sharing at the point of sale, chairman Chuck Grassley, R-IA, said during a committee markup of the bill 25 July.

The legislation passed the committee in a 19-9 vote with no major amendments

More from Pricing Debate

More from Market Access